Indirect immunofluorescence assays (IFAs) have been used to show that sera from patients with Lyme disease often have antibodies that bind to spirochetes isolated from Ixodes dammini ticks [ 1, 2] . Peak IgM titers occur three to six weeks after onset of erythema chronicum migrans (ECM), with a geometric mean titer (GMT) of 178; peak IgG titers with a GMT of 641 occur months later in sera from patients with arthritis [2] . IgG and occasionally IgM titers tend to persist for at least several years in patients with recurrent attacks of arthritis. The potential usefulness of antibody determinations in diagnosing Lyme disease was noted [1, 2] .
At the Centers for Disease Control (CDC), we standardized an IFA and evaluated an enzyme-linked immunosorbent assay (ELISA) as serodiagnostic aids for Lyme disease [3] . We showed that, with reasonable precautions, either test could be used with a high degree of sensitivity and specificity for diagnosis of complicated Lyme disease.
TEST METHODOLOGY The IFA used at CDC (Appendix I) differs in several ways from the one described by Steere et al. [2] . First, we used an acetone-fixed, whole-cell antigen prepared from strain B31 (from Barbour) To determine whether the timing of the serum specimen influenced the low sensitivity of the tests on sera drawn during the ECM stage, we determined the mean day of illness from onset to serum collection for patients with active ECM: 23 days vs. 19 days for positive and negative IFA results, and 21 days vs. 21 days for positive and negative ELISA results. Therefore, the stage of the disease, instead of the timing of the serum specimen, appeared to be the more important determinant of test sensitivity. Similarly, only 27 percent of the patients with ECM alone showed seroconversion by IFA (at least fourfold increase in titer to . 256), but 60 percert of the patients with complicated cases showed seroconversion. Of added interest was the observation that 86 percent of the sera drawn from seven patients while they were in remission from ECM but before complications developed, had positive IFA titers (vs. 56 percent of the ECM patients in whom complications never developed); 100 percent of the sera from the seven patients in remission (vs. 67 percent who had no subsequent disease) had positive ELISA results.
To estimate test specificity, IFA titers and ELISA OD ratios were determined on sera from 106 patients with similar clinical manifestations, related etiologic agents, or possible cross-reactive antigens (e.g., legionellosis). The only significant crossreactions were observed with sera from patients with treponemal diseases ( Table 2 ). The IFA was 97 percent specific if these sera were excluded and 84 percent if they were included in the analysis. Similarly, the ELISA was 100 percent specific if the treponemal sera were excluded and 92 percent if they were included. Also shown in Table 2 [2] found that spirochetal strains isolated from different sources, including tick and human, gave the same serologic results when they were used as IFA antigens for human serum titrations. Lowering the cutoff level for a positive test result gave minimal improvement in sensitivity, whereas the specificity was lowered by 9 percent for ELISA and 10 percent for IFA. A comparison of IFA titers obtained with class-specific conjugates and the polyvalent conjugate showed that serologic reactivity was primarily due to IgG during complicated Lyme disease, whereas IgM contributed more to the reaction during ECM. This is in agreement with Steere's observations [2] . In our study, titers with the polyvalent conjugate were the same or slightly greater than titers obtained with monovalent conjugates. Therefore, routinely using conjugates specific for IgG or IgM offered no apparent advantage.
FUTURE USE In 1983, CDC began testing serum specimens submitted through state health laboratories from patients with suspected Lyme disease. By late summer, we had determined IFA titers for 289 patients from 38 states (excluding sera obtained in special surveys). Seventy-four (26 percent) had titers .256. As expected, the preponderance of sera were submitted from states known to be endemic for the disease: Massachusetts, New Jersey, Minnesota, and Maryland. Data are being analyzed for the entire 1983 tick season, and the preliminary analyses suggest that Lyme disease may be occurring more widely than has been previously appreciated. All but two (Eastsouth Central and Westsouth Central) of nine U.S. regions submitted at least one positive serum sample. The place of exposure of these patients must still be determined. Because of the difficulty in culturing the spirochete and demonstrating its presence in tissue, serologic testing will be relied on heavily as an aid in diagnosing the disease and also in estimating disease prevalence. Of the two tests developed for this purpose, the ELISA has several advantages over the IFA: greater sensitivity during the ECM stage, less subjective readings, potential for automation, and the possibility of using a purified, specific antigen. Efforts are in progress to further improve the ELISA for routine use.
APPENDIX I Indirect immunofluorescence assay (IFA) for Lyme disease [3] 1. Grow spirochetes in suitable medium, such as BSK [4] 
